Today: 19 May 2026
Browse Category

LSE:GRG 5 December 2025 - 9 February 2026

UK stock market today: FTSE 100 slips as Starmer turmoil weighs; NatWest deal and Greggs downgrade in focus

UK stock market today: FTSE 100 slips as Starmer turmoil weighs; NatWest deal and Greggs downgrade in focus

London’s FTSE 100 slipped 0.1% to 10,360.11 in morning trade, as political turmoil around Prime Minister Keir Starmer unsettled markets. NatWest shares dropped 4.5% after agreeing to buy Evelyn Partners for £2.7 billion. The pound was steady at $1.3607, while the 10-year gilt yield reached 4.554%. Gold topped $5,000 and Brent crude hovered near $68 a barrel.
9 February 2026
···
Best UK Stocks to Buy Now (5 December 2025): 10 Shares to Watch as the FTSE 100 Nears Record Highs

Best UK Stocks to Buy Now (5 December 2025): 10 Shares to Watch as the FTSE 100 Nears Record Highs

The FTSE 100 is up about 22–23% year-to-date as of December 5, 2025, and sits less than 2% below its record closing high. Today, the FTSE 100 rose 0.2% and the FTSE 250 gained 0.4%, with AstraZeneca and Ocado among notable risers. Markets expect the Bank of England to cut rates from 4% to 3.75% on December 18. UK equities continue to trade at a discount to global peers.
5 December 2025
·······

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

18 May 2026
Intel shares rose 0.3% to $109.10 in early New York trading Monday after last week’s selloff, as analysts raised price targets and President Trump commented on the U.S. government’s 10% stake, now valued above $50 billion. First-quarter revenue climbed 7% to $13.6 billion, with Data Center and AI sales up 22%. The iShares Semiconductor ETF fell 0.9%. Intel’s server CPU market share dropped to 54.9% in Q1, according to UBS.
Go toTop